Gert Van Assche
About
In The Last Decade
Gert Van Assche
461 papers receiving 35.9k citations
Hit Papers
Peers
Comparison fields: 5 of 156
- Genetics 26.9k
- Epidemiology 20.6k
- Surgery 10.7k
- Immunology 8.9k
- Molecular Biology 3.2k
Countries citing papers authored by Gert Van Assche
This map shows the geographic impact of Gert Van Assche's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gert Van Assche with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gert Van Assche more than expected).
Fields of papers citing papers by Gert Van Assche
This network shows the impact of papers produced by Gert Van Assche. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gert Van Assche. The network helps show where Gert Van Assche may publish in the future.
Co-authorship network of co-authors of Gert Van Assche
This figure shows the co-authorship network connecting the top 25 collaborators of Gert Van Assche. A scholar is included among the top collaborators of Gert Van Assche based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gert Van Assche. Gert Van Assche is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 5 | |
| 3 | 80 | |
| 4 | 32 | |
| 5 | Effects of introduction of an inflammatory bowel diseases nurse position on the quality of delivered care | 1 |
| 6 | A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease | 2 |
| 7 | Intestinal microbial signature predicts postoperative Crohn's disease recurrence following ileocaecal resection with ileocolonic anastomosis | 1 |
| 8 | Disease burden outweighs the impact of drug concentrations and antibodies to infliximab in primary non-response to infliximab in Crohn's disease patients | 2 |
| 9 | Long-term outcome of IBD patients with primary non-response to anti-TNF therapy | 3 |
| 10 | Anti-TNF treatment and renal cell carcinoma in patients with inflammatory bowel disease, rheumatoid arthritis and spondyloarthropathy: trigger or cure? | 1 |
| 11 | Tolerability of Shortened Infliximab Infusion in Scheduled Maintenance Therapy for IBD: A Prospective Multi-center European Cohort Study | 1 |
| 12 | Prognostic Value of Serologic and Histologic Markers on Long-Term Outcomes in Ulcerative Colitis Patients With Mucosal Healing | 5 |
| 13 | 32 | |
| 14 | Anti-TNF induced skin manifestations in IBD patients: characterization and search for predisposing factors | 5 |
| 15 | Long term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease | 2 |
| 16 | Effect of infliximab treatment on colonic mucosal gene expression profiles in patients with inflammatory bowel disease | 1 |
| 17 | The ideal management of Crohn's disease: Top down versus step up strategies, a randomized controlled trial | 29 |
| 18 | A panel of anti-glycan antibodies (gASCA, ALCA, ACCA and AMCA) in the diagnosis and differential diagnosis of IBD | 1 |
| 19 | A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): Top-down versus step-up strategies | 24 |
| 20 | Randomized placebo controlled trial of pro- and prebiotics (synbiotics cocktail) for maintenance of infliximab induced remission of luminal Crohn's disease (CD) | 11 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.